title: Linezolid as a Potentially Effective Drug for the Treatment of Multidrug-Resistant Tuberculosis in Japan.
abstract: Linezolid (LZD) is classified as a WHO group 5 drug used in the treatment of tuberculosis (TB). Although its efficacy and long-term safety have not yet been established, it is being increasingly used in the treatment of multidrug resistant tuberculosis (MDR-TB) and extensive multidrug-resistant tuberculosis (XDR-TB). The current study is a single-center retrospective clinical analysis of hospitalized M/XDR-TB patients in Fukujuji Hospital involving 26 patients (18 men and 8 women) consecutively treated with combinations of anti-TB drugs including LZD from 2009 to 2015. The sputum culture results were negative after using LZD for an average period of 28.0 ± 12.0 (average ± SD) days. LZD was reduced or withdrawn in 11 cases due to adverse effects. Nineteen cases including 3 XDR-TB patients were operated on, and their TB was treated following surgery. The average time from the initiation of LZD therapy to surgery was 87.6 ± 38.7 (average ± SD) days. Favorable clinical outcome was maintained in 23 surviving patients, while 3 patients died during treatment because of end stage cancer and aspiration pneumonia. Our study showed that LZD might be clinically effective in the treatment of M/XDR-TB patients in Japan.
authors.affiliation: Respiratory Disease Center, Fukujuji Hospital.
authors.forename: Lina
authors.initials: L
authors.lastname: Yi
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshiyama
authors.forename: Masao
authors.initials: M
authors.lastname: Okumura
authors.forename: Kozo
authors.initials: K
authors.lastname: Morimoto
authors.forename: Yuka
authors.initials: Y
authors.lastname: Sasaki
authors.forename: Yuji
authors.initials: Y
authors.lastname: Shiraishi
authors.forename: Hideo
authors.initials: H
authors.lastname: Ogata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Mitarai
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D000069349:Linezolid / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D028761:Withholding Treatment
chemical_list: D000900:Anti-Bacterial Agents; D000069349:Linezolid